Search results
Results from the WOW.Com Content Network
T-cells are white blood cells that play a key role in the body’s immune response. The study arrived at its findings by comparing blood samples from 19 people with lupus to blood samples from ...
Initially, these lipid droplets were considered to merely serve as fat depots, but since the discovery in the 1990s of proteins in the lipid droplet coat that regulate lipid droplet dynamics and lipid metabolism, lipid droplets are seen as highly dynamic organelles that play a very important role in the regulation of intracellular lipid storage ...
For example, the T- cells may not be activated and sustain the anti-tumor effect long enough, or the number of T-cells presented is insufficient. TIL therapy isolates tumor-infiltrating lymphocytes (TILs), which are naturally occurring T cells in cancer patients that have already recognised cancer cells and infiltrated into the tumor as an anti ...
More recently in 2023, Tontonoz identified CLSTN3β as a novel ER-lipid droplet contact protein that governs lipid utilization in adipocytes. He showed that the distinctive role of this protein in inhibiting lipid droplet coalescence resolves the question of why brown fat cells harbor numerous small lipid droplets while white fat cells possess ...
The lipid droplet's function is to store energy for the organism's body and is found in every type of adipocytes. They can consist of a vacuole, droplet of triglyceride, or any other blood lipid, as opposed to fat cells in between other cells in an organ. They contain a hydrophobic core and are encased in a phospholipid monolayer membrane. Due ...
Childhood-onset systemic lupus erythematosus (i.e., cSLE), also termed juvenile-onset systemic lupus erythematosus, juvenile systemic lupus erythematosus, and pediatric systemic lupus erythematosus, is a form of the chronic inflammatory and autoimmune disease, systemic lupus erythematosus (i.e., SLE), that develops in individuals up to 18 years old. [1]
Treatment for a lupus anticoagulant is usually undertaken in the context of documented thrombosis, such as extremity phlebitis or dural sinus vein thrombosis. Patients with a well-documented (i.e., present at least twice) lupus anticoagulant and a history of thrombosis should be considered candidates for indefinite treatment with anticoagulants.
In oncology, our leading bispecific T cell engager platform provides further opportunities for growth, with BLINCYTO moving into front-line treatment and demonstrating compelling survival benefit ...